The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer
Open accessAbstract
Relapse to anti-HER2 monoclonal antibody (mAb) therapies, such as trastuzumab in HER2 + breast cancer (BC), is associated with residual disease progression due to resistance to therapy. Here, we identify interferon-γ inducible protein 16 (IFI16)-dependent STING signaling as a significant determinant of trastuzumab responses in HER2 + BC. We show that down-regulation of immune-regulated genes (IRG) is specifically associated with poor survival of HER2 + , but not other BC subtypes. Among IRG, IFI16 is identified as a direct target of EZH2, the underexpression of which leads to deficient STING activation and downstream CXCL10/11 expression in response to trastuzumab treatment. Dual inhibition of EZH2 and histone deacetylase (HDAC) significantly activates IFI16-dependent immune responses to trastuzumab. Notably, a combination of a novel histone methylation inhibitor with an HDAC inhibitor induces complete tumor eradication and long-term T cell memory in a HER2 + BC mouse model. Our findings demonstrate an epigenetic regulatory mechanism suppressing the expression of the IFI16-CXCL10/11 signaling pathway that provides a survival advantage to HER2 + BC to confer resistance to trastuzumab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationDenkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,358
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Self-citationIn vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895
Self-citationSTING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Nuclear cGAS suppresses DNA repair and promotes tumorigenesis
Liu, H., Zhang, H., Wu, X., Ma, D., Wu, J., Wang, L., Jiang, Y., Fei, Y., Zhu, C., Tan, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0629-6 · Cited by 650
Self-citationDunphy, G., Flannery, S. M., Almine, J. F., Connolly, D. J., Paulus, C., Jønsson, K. L., Jakobsen, M. R., Nevels, M. M., Bowie, A. G., & Unterholzner, L. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.034 · Cited by 648
cGAS-STING, an important pathway in cancer immunotherapy
Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647
Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., de Azambuja, E., Eidtmann, H., Ellis, C. E., Baselga, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0830 · Cited by 605
Hurvitz, S. A., Martin, M., Symmans, W. F., Jung, K. H., Huang, C.-S., Thompson, A. M., Harbeck, N., Valero, V., Stroyakovskiy, D., Wildiers, H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30716-7 · Cited by 534
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Lee, S. T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R. K. M., Liou, Y. C., & Yu, Q. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.011 · Cited by 399
Self-citationIFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes
Almine, J. F., O’Hare, C. A. J., Dunphy, G., Haga, I. R., Naik, R. J., Atrih, A., Connolly, D. J., Taylor, J., Kelsall, I. R., Bowie, A. G., et al. (2017) · Nature Communications · doi:10.1038/ncomms14392 · Cited by 340
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Byrne, A., Savas, P., Sant, S., Li, R., Virassamy, B., Luen, S. J., Beavis, P. A., Mackay, L. K., Neeson, P. J., & Loi, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0333-y · Cited by 301
Trial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289
IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP
Jønsson, K. L., Laustsen, A., Krapp, C., Skipper, K. A., Thavachelvam, K., Hotter, D., Egedal, J. H., Kjolby, M., Mohammadi, P., Prabakaran, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14391 · Cited by 283
Wu, S., Zhang, Q., Zhang, F., Meng, F., Liu, S., Zhou, R., Wu, Q., Li, X., Shen, L., Huang, J., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0352-z · Cited by 275
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., Xu, P., Tan, J., Rui, Y., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep19049 · Cited by 253
Filho, O. M., Viale, G., Stein, S., Trippa, L., Yardley, D. A., Mayer, I. A., Abramson, V. G., Arteaga, C. L., Spring, L. M., Waks, A. G., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1557 · Cited by 252
Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00185-w · Cited by 250
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.
Drebin, J. A., Link, V. C., Weinberg, R. A., & Greene, M. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.23.9129 · Cited by 233
Immunotherapy for Breast Cancer: What Are We Missing?
Vonderheide, R. H., Domchek, S. M., & Clark, A. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2569 · Cited by 233
Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors
Nirmal, A. J., Regan, T., Shih, B. B., Hume, D. A., Sims, A. H., & Freeman, T. C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0342 · Cited by 218
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205
Ohkuri, T., Kosaka, A., Ishibashi, K., Kumai, T., Hirata, Y., Ohara, K., Nagato, T., Oikawa, K., Aoki, N., Harabuchi, Y., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1975-1 · Cited by 201
RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma
Lam, A. R., Le Bert, N., Ho, S. S. W., Shen, Y. J., Tang, M. L. F., Xiong, G. M., Croxford, J. L., Koo, C. X., Ishii, K. J., Akira, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1703 · Cited by 179
Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34537 · Cited by 179
Yan, J., Ng, S.-B., Tay, J. L.-S., Lin, B., Koh, T. L., Tan, J., Selvarajan, V., Liu, S.-C., Bi, C., Wang, S., et al. (2013) · Blood · doi:10.1182/blood-2012-08-450494 · Cited by 164
Self-citationYang, X., Karuturi, R. K. M., Sun, F., Aau, M., Yu, K., Shao, R., Miller, L. D., Tan, P. B. O., & Yu, Q. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005011 · Cited by 164
Self-citationGriguolo, G., Pascual, T., Dieci, M. V., Guarneri, V., & Prat, A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0548-6 · Cited by 124
Roles of the cGAS-STING Pathway in Cancer Immunosurveillance and Immunotherapy
Yum, S., Li, M., Frankel, A. E., & Chen, Z. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055636 · Cited by 110
Wee, Z. N., Li, Z., Lee, P. L., Lee, S. T., Lim, Y. P., & Yu, Q. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.045 · Cited by 106
Self-citationSzöőr, Á., Tóth, G., Zsebik, B., Szabó, V., Eshhar, Z., Abken, H., & Vereb, G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.008 · Cited by 105
Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martinez‐García, M., Rovira, A., Rojo, F., Albanell, J., & López‐Botet, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01544 · Cited by 97
Ignatiadis, M., den Eynden, G. V., Salgado, R., Fornili, M., Barèche, Y., Desmedt, C., Rothé, F., Maetens, M., Venet, D., Holgado, E., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy076 · Cited by 97
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
Mandó, P., Rivero, S. G., Rizzo, M., Pinkasz, M., & Levy, E. M. (2021) · The Breast · doi:10.1016/j.breast.2021.08.007 · Cited by 90
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Self-citationHuober, J., Holmes, E. M., Baselga, J. M., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Láng, I., Smith, I., Boyle, F. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.038 · Cited by 82
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Sun, F., Chan, E., Wu, Z., Yang, X., Márquez, V. E., & Yu, Q. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0479 · Cited by 69
Self-citationEZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Bao, Y., Oguz, G., Lee, W. C., Lee, P. L., Ghosh, K., Li, J., Wang, P., Lobie, P. E., Ehmsen, S., Ditzel, H. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19704-x · Cited by 64
Self-citationLeVasseur, N., Sun, J., Gondara, L., Diocee, R. M., Speers, C. H., Lohrisch, C. A., & Chia, S. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03083-y · Cited by 60
Koyen, A. E., Madden, M. Z., Park, D., Minten, E. V., Kapoor-Vazirani, P., Werner, E., Pfister, N. T., Haji‐Seyed‐Javadi, R., Zhang, H., Xu, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1332-2 · Cited by 60
Truax, A. D., Thakkar, M., & Greer, S. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036013 · Cited by 50
Li, P., Yang, L., Li, T., Bin, S., Sun, B., Huang, Y., Yang, K., Shan, D., Gu, H., & Li, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01143 · Cited by 49
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Hirukawa, A., Singh, S., Wang, J. H., Rennhack, J. P., Swiatnicki, M., Sanguin‐Gendreau, V., Zuo, D., Daldoul, K., Lavoie, C. A., Park, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.105 · Cited by 45
Shared Antigenic Epitopes and Pathobiological Functions of Anti-p185 Monoclonal Antibodies
Zhang, H., Wang, Q., Montone, K. T., Peavey, J. E., Drebin, J. A., Greene, M. I., & Murali, R. (1999) · Experimental and Molecular Pathology · doi:10.1006/exmp.1999.2266 · Cited by 44
Singla, H., Ludhiadch, A., Kaur, R. P., Chander, H., Kumar, V., & Munshi, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.075 · Cited by 40
Li, Y., Li, S., Chen, J., Shao, T., Jiang, C., Wang, Y., Chen, H., Xu, J., & Li, X. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu256 · Cited by 34
Kuznetsova, M. S., Lopatnikova, J., Shevchenko, J. A., Силков, А. Н., Maksyutov, A. Z., & Sennikov, S. V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01017 · Cited by 33
Association between frequent CpG island methylation and HER2 amplification in human breast cancers
Terada, K., Okochi‐Takada, E., Akashi‐Tanaka, S., Miyamoto, K., Taniyama, K., Tsuda, H., Asada, K., Kaminishi, M., & Ushijima, T. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp021 · Cited by 31
3‐Deazaneplanocin A and Neplanocin A Analogues and Their Effects on Apoptotic Cell Death
Tam, E. K. W., Nguyen, T. M., Lim, C. Z. H., Lee, P. L., Li, Z., Jiang, X., Santhanakrishnan, S., Tan, T. W., Goh, Y. L., Wong, S. Y., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201402315 · Cited by 26
Self-citationJiang, X., Lim, C. Z. H., Li, Z., Lee, P. L., Yatim, S. M. J. M., Guan, P., Li, J., Zhou, J., Pan, J., Chng, W. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122983 · Cited by 21
Self-citationZhang, F., Zhang, J., Liu, M., Zhao, L., Linghu, R., Feng, F., Gao, X., Jiao, S., Zhao, L., Hu, Y., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994391 · Cited by 19
Cited by
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Cui, B., Ding, Y., & Li, C. (2025) · Discovery Medicine · doi:10.24976/discov.med.202537203.245 · Cited by 1
Metadata
- Authors
- Ong, L.-T., Lee, W. C., Ma, S., Oguz, G., Niu, Z., Bao, Y., Yusuf, M., Lee, P. L., Goh, J. Y., Wang, P., Yong, K. S. M., Chen, Q., Wang, W., Ramasamy, A., Hoon, D. S. B., Ditzel, H. J., Tan, E. Y., Lee, S. C., & Yu, Q.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2022-07-25
- Volume
- 119
- Issue
- 31
- Pages
- e2201376119-e2201376119
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W4287577366
- Cited by
- 572
- References
- 62
- FWCI
- 51.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.